LOUISVILLE, Ky., Oct. 24, 2022 (GLOBE NEWSWIRE) -- An overwhelming majority of Kentuckians favor a national government health plan, according…
Pre-clinical trial demonstrates ability of nVNS to decrease amount of brain injury, decrease anxiety and improve motor function post injuryROCKAWAY,…
AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared…
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations,…
TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- VITALHUB CORP. (TSX: VHI) (the “Company” or “VitalHub”) is pleased to announce today…
US Insurance Award Recognizes Their Innovative Solution for Managing Return-to-Work and Temporary Total DisabilityFORT WORTH, Texas, Oct. 11, 2022 (GLOBE…
LAVAL, Québec, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST),…
ReWalk to submit first cases for Medicare coverage through Medicare Administrative Contractors (MACs)Centers for Medicare and Medicaid Services (CMS) affirms…
New Patents Issued and Fast Track Designation Support Development of the Only Locally-Administered Drug Treatment for TGCT Positive Proof-of-Concept Results…
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis MoonLake announces…